Lentiviral CRISPR/Cas9-Mediated Genome Editing for the Study of Hematopoietic Cells in Disease Models
October 3rd, 2019
11.6K views
Described are protocols for the highly efficient genome editing of murine hematopoietic stem and progenitor cells (HSPC) by the CRISPR/Cas9 system to rapidly develop mouse model systems with hematopoietic system-specific gene modifications.
Overview
This article presents a method for efficient genome editing of murine hematopoietic stem and progenitor cells (HSPC) using the CRISPR/Cas9 system. The protocol allows for rapid development of mouse models with specific gene modifications in the hematopoietic system.
Key Study Components
Area of Science
- Genetics
- Stem Cell Biology
- Mouse Models
Background
- Genome editing is crucial for studying gene function.
- Hematopoietic stem cells are vital for blood cell development.
- Conventional methods for creating transgenic mice are often time-consuming and costly.
- The CRISPR/Cas9 system offers a more efficient alternative.
Purpose of Study
- To establish a cost-effective method for gene manipulation in hematopoietic stem cells.
- To create mouse models with specific mutations in hematopoietic cells.
- To demonstrate the advantages of using lentivirus-mediated transgene delivery systems.
Methods Used
- Preparation of lentivirus particles using 293T cells.
- Transfection of cells with a mixture of plasmids.
- Collagen coating of plates for cell culture.
- Incubation conditions set at 37 degrees Celsius and 5% carbon dioxide.
Main Results
- Successful establishment of gene-edited mice.
- Demonstrated rapid creation of specific mutations.
- Cost-effective compared to traditional methods.
- Potential for broad applications in hematopoietic research.
Conclusions
- The protocol enhances the efficiency of generating mouse models.
- CRISPR/Cas9 technology is a powerful tool for genetic studies.
- This method can accelerate research in hematopoietic biology.
Frequently Asked Questions
What is the main advantage of this genome editing method?
The main advantage is its efficiency and cost-effectiveness compared to conventional transgenic approaches.
Who demonstrates the procedure in the article?
Ying Wang, a researcher from the laboratory, demonstrates the procedure.
What type of cells are targeted for gene editing?
The protocol targets murine hematopoietic stem and progenitor cells (HSPC).
What technology is used for gene editing in this study?
The study utilizes the CRISPR/Cas9 genome editing system.
What are the incubation conditions for preparing lentivirus particles?
The incubation conditions are set at 37 degrees Celsius and 5% carbon dioxide.
What is the purpose of using lentivirus in this protocol?
Lentivirus is used for efficient transgene delivery into hematopoietic stem cells.
Executive Industry Relevance
This method enables rapid, cost-effective generation of hematopoietic-specific gene-edited mouse models, addressing a key bottleneck in preclinical target validation. By leveraging lentiviral CRISPR/Cas9 delivery, it supports high-throughput interrogation of hematopoiesis-regulatory genes, accelerating mechanistic de-risking in early discovery. The approach enhances predictive confidence in target selection for hematological malignancies and cardiovascular disease models involving hematopoietic cell dysfunction.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables functional interrogation of gene function in hematopoietic stem cells to validate therapeutic targets.
- Operational Value: Reduces time and cost compared to conventional transgenic approaches for target validation studies.
- Predictive Value: Supports phenotypic screening of gene edits in myeloid and lymphoid lineages with ~90% and ~70% transduction efficiency, respectively.
Screening & Assay Development
- Scientific Value: Provides a standardized system for generating RFP-labeled hematopoietic cells to enable flow cytometry-based screening.
- Operational Value: Allows preparation of high-titer lentivirus stocks for reproducible transduction across experiments.
- Assay Readiness: Facilitates quantitative measurement of engraftment and lineage-specific editing via PCR validation of RFP-positive cells.
Translational & Preclinical Research
- Disease Model Relevance: Extends to mouse models of hematological malignancy and cardiovascular disease with hematopoietic involvement.
- Translational Continuity: Supports lineage-specific gene editing to study gene function in clinically relevant blood cell types.
- Preclinical De-risking: Enables evaluation of on-target effects and mutation profiles (e.g., 69% out-of-frame or premature stop mutations) to inform target safety.
Pipeline & Workflow Integration
The method fits within the discovery-to-preclinical continuum, enabling target validation through hematopoietic-specific gene editing prior to lead optimization.
- Discovery Biology: Supports hypothesis testing by enabling rapid generation of allele-specific mutations in HSPCs to clarify gene function in blood cell development.
- Screening: Delivers assay-ready, genetically modified hematopoietic cells with fluorescent tracking for standardized compound or genetic screening.
- Analytics: Provides quantitative outputs including flow cytometry-based engraftment metrics and PCR-amplified genomic validation of editing efficiency.
- Translational Research: Connects discovery findings to preclinical validation through disease-relevant hematopoietic models.
- Enterprise Reuse: Establishes a reusable platform for generating multiple hematopoietic disease models from a single lentiviral library.
Operational & Enterprise Impact
- Scientific Value: Increases target validation confidence through precise, lineage-restricted genome editing in hematopoietic systems.
- Operational Value: Enhances reproducibility via standardized lentivirus production and transduction protocols.
- Strategic Value: Improves capital efficiency by reducing reliance on time-intensive transgenic mouse generation.
- Portfolio Impact: Enables risk-adjusted target prioritization through high-throughput phenotypic assessment of hematopoietic gene function.
Implementation Considerations
- Requires expertise in lentiviral vector production, hematopoietic cell isolation, and sterile tissue culture techniques.
- Depends on access to ultracentrifugation, flow cytometry, and PCR/sequencing infrastructure for validation.
- Necessitates biosafety level 2 practices for lentivirus handling per institutional and NHA guidelines.
- Requires optimization of transduction conditions and transplantation efficiency for consistent engraftment across models.
- Limited by the need for irradiation conditioning in recipient mice, which may affect certain disease model phenotypes.
Biopharma FAQs
Why is null hypothesis testing important for target validation in hematopoietic cells?
Null hypothesis testing helps determine whether observed phenotypic changes in RFP-positive hematopoietic cells are statistically significant compared to non-targeting gRNA controls, supporting confident target validation decisions.
How does isolating lineage-negative hematopoietic stem cells as an independent variable improve discovery pipeline accuracy?
Isolating lineage-negative cells ensures that gene editing occurs in a defined progenitor population, reducing variability and enabling reproducible assessment of gene function in hematopoietic differentiation.
What quantitative dependent variable measurements enable assessment of genome editing efficiency in this method?
Flow cytometric detection of RFP-positive leukocytes in peripheral blood provides quantitative measurement of engraftment, while PCR amplification and sequencing of genomic DNA from sorted cells validate editing efficiency and mutation types.
Why are replication requirements critical for cross-functional collaboration in hematopoietic target validation studies?
Replication ensures consistent transduction efficiency (~90% myeloid, ~70% lymphoid) and editing outcomes across experiments, enabling reliable data sharing between discovery, preclinical, and translational teams.
What statistical analysis capabilities are required before implementing this lentiviral CRISPR/Cas9 method in target validation workflows?
Statistical analysis is needed to compare engraftment and editing frequencies between experimental and control groups, determine significance of phenotypic effects, and establish confidence thresholds for go/no-go decisions in target prioritization.
Chapters in this video
0:04
Title
0:46
Generation and Purification of Lentivirus Particles
3:08
Isolation and Transduction of Lineage-negative Cells from Mouse Bone Marrow
5:23
Transplantation of Transduced Cells into Lethally Irradiated Mice
5:39
Evaluating the Chimerism of Peripheral Blood
6:19
Results: Lentiviral Transduction of Mouse Bone Marrow Lineage-negative Cells
7:23
Conclusion
